Targeting mTOR dependency in pancreatic cancer

Conclusions
KRAS PTEN tumours are uniquely responsive to mTOR inhibition. Targeted anti-mTOR therapies may offer clinical benefit in subsets of human PDAC selected based on genotype, that are dependent on mTOR signalling. Thus, the genetic signatures of human tumours could be used to direct pancreatic cancer treatment in the future.

Source: Gut - August 3, 2014 Category: Gastroenterology Authors: Morran, D. C., Wu, J., Jamieson, N. B., Mrowinska, A., Kalna, G., Karim, S. A., Au, A. Y. M., Scarlett, C. J., Chang, D. K., Pajak, M. Z., Australian Pancreatic Cancer Genome Initiative (APGI), Oien, K. A., McKay, C. J., Carter, C. R., Gillen, G., Champio Tags: Pancreas and biliary tract, Open access, Pancreatic cancer Source Type: research